Bleeding risk with the new oral anticoagulant drugs (NOACs) is increased when they are used with some other medications, including amiodarone, often co-prescribed with these agents, a new study warns.

HOUSTON, TX—There’s no such thing as a good intracranial hemorrhage (ICH), but a new analysis hints that patients who have one might be better off if they’re taking a non-vitamin K antagonist oral ...

A common scenario: a patient presents with new-onset atrial fibrillation (AF) and multiple risk factors for stroke. Everyone agrees to use anticoagulant therapy to reduce the risk of stroke. The ...

Patients with nonvalvular atrial fibrillation treated with non-vitamin K oral anticoagulants (NOACs) have a heightened risk of major bleeding when also treated with other medications, including ...

BOSTON -- Lower adherence to non-vitamin K antagonist oral anticoagulant (NOACs) might wipe out the advantage over warfarin (Coumadin), according to a large real-world observational study. In an ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

A retrospective cohort study of patients with atrial fibrillation and diabetes found that the use of non–vitamin K antagonist oral anticoagulants (NOAC) was associated with a lower risk of diabetes ...

The American Journal of Managed Care® discussed an indirect comparison of andexanet alfa and prothrombin complex concentrate therapy with Alexander T. Cohen, MBBS, MSc, MD, Guy’s and St Thomas’ ...

(HealthDay News) — Non-vitamin K antagonist oral anticoagulants (NOACs) have been adopted into practice and are more frequently prescribed than vitamin K antagonists (VKAs) in the Global Registry on ...